How Safe and Innovative Are First-in-Class Drugs Approved by Health Canada: A Cohort Study

Similar documents
NICE TA Adherence Check List

NICE TA Adherence Check list April Drug Indication NICE Approval Release Date

COMMERCIAL APIs. S. No Molecule Name Therapeutic Category USDMF EDMF CEP IH

Innovative Products Available. OTC Products Available

While there is around a 3% increase shown in costs for Category M lines, I think this is due to the inclusion of more lines in Category M.

Vivida Health Specialty Pharmacy Drugs (Injectable) Prior-Authorization Requirements Effective 1/1/19

Domperidone: Drug Interactions & Cautions (Mayo Clinic)

DT Description Price Category Price change Percentage BNF 1.2 Mebeverine 135mg tablets (100) 759 M %

Orodispersible tablets & Tablets

DT Description Price Category Price change Percentage BNF 1.2 Mebeverine 135mg tablets (100) 702 M %

PORTFOLIO Q June 2014 Availability of products is subject to patent restrictions in countries where applicable patents are in effect 1/5

Our Values. Quality Intelligent efforts in everyday practice. Innovation Change that unlocks new value. Performance Passion for results

PORTFOLIO Q October 2015 Availability of products is subject to patent restrictions in countries where applicable patents are in effect 1/6

DT Description Price Category Price change Percentage

MICROMEDEX(R) Healthcare Series Integrated Index

Price comparison of high-cost medicines 2015

CLINICAL SERVICES OVERVIEW

ATYPICAL ANTIPSYCHOTICS

Alimentary Tract and Metabolism

Injections Requiring Prior Authorization

BIOANALYTICAL ASSAY LIST

PART III: CONSUMER INFORMATION

We embrace science and innovation

Hazardous Medication List

1 17 ACITRETIN 10MG CAP 20, ,000 14,000 4, ACITRETIN 25MG CAP 50, ,000 35,000 10,000

Royal Free London NHS Foundation Trust NICE Technology Appraisals and Drug Formulary Indications to date

DT Description Price Category Price change

Drug Name. J0129 Injection, abatacept (Orencia ), 10 mg Effective 01/01/2014. J0178 Injection, aflibercept (Eylea ), 1 mg Effective 04/01/2015

SUPPLEMENTARY INFORMATION In format provided by Czerepak and Ryser (MARCH 2008)

The following are J Code requirements

Hospital Prescribing: England 2012

Medicare Part D 2012 Formulary Changes Service To Senior and Total Fit

PRODUCT MONOGRAPH. itraconazole. oral solution 10 mg/ml. Antifungal Agent. Janssen Inc. 19 Green Belt Drive Toronto, Ontario M3C 1L9

The Royal Marsden NHS Foundation Trust Medicines Formulary. NICE register for medicines initiated at the trust. Type and code. Publication.

SPORANOX Oral Solution Itraconazole

MEDICAL NECESSITY GUIDELINE

SPORANOX Capsules Itraconazole

Medicines Procurement South West

Provider Administered Drug Program (PADP) and Physician Administered Drug VPSS List

NICE-approved drugs for specialities which fall outside of the services currently provided by the Trust

Product Name Strength Dosage Form Therapeutic Area Dossier Status. Aceclofenac 100mg Film coated Tablets Analgesia-inflammation Approved

The Royal Marsden NHS Foundation Trust Medicines Formulary. NICE register for medicines initiated at the trust. Type and code. Publication.

SPORANOX. itraconazole NEW ZEALAND DATA SHEET

TRICARE Uniform Formulary. Pre-Authorization Requirements

SPORANOX. itraconazole NEW ZEALAND DATA SHEET

A BULLETIN FOR PHARMACY SERVICE PROVIDERS FROM ALBERTA BLUE CROSS. Pan-Canadian Select Molecule Price Initiative for Generic Drugs

Index. Nurs Clin N Am 40 (2005) Note: Page numbers of article titles are in boldface type.

Prevention and Management of chemo-and radiotherapy-induced nausea and vomiting

Applications for new human medicines under evaluation by the Committee for Medicinal Products for Human Use

Before you take Itrazole

NATIVA GROUP. Inspired by Innovation and Technology

GPOR Bosentan, Dronedarone and Tadalafil Tablets - Item 1 DKSH (Offer 2)

Protocol Number Tumour Group Protocol Name on NCCP website 22/02/ Lung Afatinib Monotherapy 244 Gastrointestinal Regorafenib Monotherapy

Medicines Formulary BNF Section 4 Central Nervous System

PRODUCT MONOGRAPH. itraconazole. oral solution 10 mg/ml. Antifungal Agent. Date of Preparation: June 6, 2002

List of Designated High-Cost Drugs

Protocol Number Intrathecal Methotrexate for CNS 01/02/2018 Prophylaxis in GTN Gynaecology 249

SPORANOX Oral Solution Itraconazole Consumer Medicine Information

VMG Pharmaceuticals Pvt. Ltd.

BCBS AZ ADV PLUS * CLASSIC * PREMIER For use with members associated with the BHN Network Prior Authorization List 2015

NEW ZEALAND DATA SHEET

Orchid Chemicals & Pharmaceuticals Ltd. Orchid Towers 313, Valluvar Kottam High Road, Nungambakkam, Chennai , India. Tel : (91)

DOXOrubicin, Cyclophosphamide (AC 60/600) 21 day followed by weekly PACLitaxel (80) Therapy (AC-T) 261 CARBOplatin (AUC4-6) Monotherapy-21 days

Manufacturer: Janssen Cilag for Tibotec Therapeutics, Division of Centocor Ortho Biotech Products (1)

The Royal Marsden NHS Foundation Trust Medicines Formulary. NICE register for medicines initiated at the trust. Type and code. Publication.

Table 1 Details of products supplied and the correlation coefficient of each of these products against its reference.

STEP THERAPY PROGRAM

ANTIRETROVIRAL CONTRAINDICATIONS AND DRUG INTERACTIONS (Part 1 of 8) 10)

DRUG GUIDELINE. AMIODARONE (Intravenous)

Description The following are synthetic cannabinoids requiring prior authorization: dronabinol (Marinol, Syndros ), nabilone (Cesamet )

PHARMACY PEARLS CHANIN WRIGHT, PHARMD

Sporanox 100 mg capsules

DOSSIER LIST. tlo_seledyn.pdf :38:01 CMY K CM MY CY

Use of Prophylactic Growth Factors and Antimicrobials in Elderly Patients with Cancer: A

current patent) ----Key intermediates for Sartan series,tatin series,liptin iiiprostaglandin Derivatives---Cloprostenol Key intermediates etc.

ICON Formulary - October 2018 Legend - ICON Protocols Essential (previously Standard), Core, Enhanced Core, Enhanced Enhanced

SPORANOX Capsules Itraconazole Consumer Medicine Information

Guidelines on Chemotherapy-induced Nausea and Vomiting in Pediatric Cancer Patients

Analyte(s) Therapeutic Method of Calibration Curve Biological Class Analysis Range Matrix

ASEBP and ARTA TARP Drugs and Reference Price by Categories

ANNOUNCEMENT. Dear Valued Customer:

MedStar Medicare Choice Pharmacy Services

SUPPLEMENTARY INFORMATION

Genetics in Cancer Therapy. Raju Kucherlapati, Ph.D. Harvard Medical School

Commissioning policies agreed by PCTs in Yorkshire and the Humber at Board meeting of YH SCG on December

CIC / WHO TB Incidence Rates. TB Registry. Literature. IGRA positive First positive IGRA test TB Registry Date IGRA

Review of predictive biomarkers in European Medicines Agency (EMA) drugs

BULLETIN # 78. Manitoba Drug Benefits and Interchangeability Formulary Amendments. The following amendments will take effect on July 17, 2014

HEALTHCARE EFFECTIVENESS DATA AND INFORMATION SET (HEDIS )

NEW PATENTED MEDICINES REPORTED TO PMPRB 2011 (UPDATE AS OF NOVEMBER 30, HIGHLIGHTED)

RAHF PFM ALPHANINE SD COAGULATION FACTOR IX J7193 COAGULATION FACTOR IX (RFIXFC)

BULLETIN # 101. Manitoba Drug Benefits and Interchangeability Formulary Amendments. The following amendments will take effect on October 18, 2018

CPT Service Description Effective Date

Monitoring Usage in Wales of Medicines Appraised by NICE and AWMSG

Kern Pharma Portfolio 2014

Funding Medicines in New Zealand: Revision of the Medicines Waiting List to 30 June 2018

AVAILABLE DOSSIERS. Product name Pharmaceutical form Strength Reference Therapeutic class

Transcription:

RESEARCH PAPER How Safe and Are First-in-Class Drugs Approved by Health Canada: A Cohort Study L innocuité et l aspect innovant des nouvelles classes de médicaments approuvés par Santé Canada : une étude de cohorte JOEL LEXCHIN Appendix 1. List of drugs with first-in-class and innovation status and Anatomical Therapeutic Chemical group Abiraterone Yes Yes antineoplastic and immunomodulating agents Abatacept Yes No antineoplastic and immunomodulating agents Abacavir No No anti-infective for systemic use Acamprosate Yes No nervous system Adalimumab No No antineoplastic and immunomodulating agents Adefovir No No anti-infective for systemic use Agalsidase beta Yes No alimentary tract and metabolism Alatrofloxacin No No anti-infective for systemic use Alefacept Yes No antineoplastic and immunomodulating agents Alemtuzumab Yes Yes antineoplastic and immunomodulating agents Alfuzosin No No genito-urinary system and sex hormones Alglucosidase alfa Yes Yes alimentary tract and metabolism Aliskiren No No cardiovascular system Alitretinoin No No antineoplastic and immunomodulating agents Almotriptan No No nervous system Ambrisentan No No cardiovascular system Amprenavir No No anti-infective for systemic use Anakinra Yes No antineoplastic and immunomodulating agents Anidulafungin No No anti-infective for systemic use [1] HEALTHCARE POLICY Vol.12 No.2, 2016

Joel Lexchin Aprepitant Yes No alimentary tract and metabolism Aripiprazole Yes No nervous system Atazanavir No No anti-infective for systemic use Atomoxetine Yes No nervous system Atorvastatin No No cardiovascular system Azacitidine Yes Yes antineoplastic and immunomodulating agents Basiliximab No No antineoplastic and immunomodulating agents Becaplermin Gel Yes No dermatologicals Belimumab Yes No antineoplastic and immunomodulating agents Besifloxacin No No sensory organs Bevacizumab Yes No antineoplastic and immunomodulating agents Bimatoprost No No sensory organs Bivalirudin No No blood and blood-forming agents Bortezomib Yes No antineoplastic and immunomodulating agents Bosentan Yes Yes cardiovascular system Botulinum toxin type B No No musculoskeletal system Brimonidine No No sensory organs Brinzolamide No No sensory organs Cabazitaxel No No antineoplastic and immunomodulating agents Cabergoline No No nervous system Canakinumab No Yes antineoplastic and immunomodulating agents Candesartan No No cardiovascular system Capecitabine No No antineoplastic and immunomodulating agents Caspofungin Yes Yes anti-infective for systemic use Celecoxib Yes No musculoskeletal system Cerivastatin No No cardiovascular system Certolizumab pegol No No antineoplastic and immunomodulating agents Cetrorelix No No systemic hormonal preparations, excluding sex hormones and insulins Cetuximab Yes No antineoplastic and immunomodulating agents Ciclesonide No No respiratory system Cidofovir No No anti-infective for systemic use Cinacalcet Yes Yes systemic hormonal preparations, excluding sex hormones and insulins [2] HEALTHCARE POLICY Vol.12 No.2, 2016

How Safe and Are First-in-Class Drugs Approved by Health Canada: A Cohort Study Citalopram No No nervous system Clofarabine No Yes antineoplastic and immunomodulating agents Clopidogrel No No blood and blood-forming agents Collagenase clostridium histolyticum Yes Yes musculoskeletal system Crizotinib Yes No antineoplastic and immunomodulating agents Dabigatran No No blood and blood-forming agents Daclizumab Yes No antineoplastic and immunomodulating agents Dalfopristin Yes No anti-infective for systemic use Daptomycin Yes No anti-infective for systemic use Darbepoetin alfa No No blood and blood-forming agents Darifenacin No No genitourinary system and sex hormones Darunavir No Yes anti-infective for systemic use Dasatinib No Yes antineoplastic and immunomodulating agents Deferasirox No No various Degarelix No No antineoplastic and immunomodulating agents Delavirdine No No anti-infective for systemic use Denosumab Yes No musculoskeletal system Desloratadine No No respiratory system Desvenlafaxine No No nervous system Dexmedetomidine No No nervous system Dienogest No No genitourinary system and sex hormones Docosanol Yes No dermatologicals Dolasetron No No alimentary tract and metabolism Donepezil No Yes nervous system Doripenem No No anti-infective for systemic use Doxercalciferol No No systemic hormonal preparations, excluding sex hormones and insulins Dronedarone No No cardiovascular system Drospirenone No No genitourinary system and sex hormones Drospirenone/ethinyl estradiol No No genitourinary system and sex hormones Drotrecogin alfa Yes Yes blood and blood-forming agents Duloxetine No No nervous system Dutasteride No No genitourinary system and sex hormones [3] HEALTHCARE POLICY Vol.12 No.2, 2016

Joel Lexchin Eculizumab Yes No antineoplastic and immunomodulating agents Efalizumab Yes No antineoplastic and immunomodulating agents Efavirenz No Yes anti-infective for systemic use Eflornithine Yes No dermatologicals Eletriptan No No nervous system Eltrombopag No No blood and blood-forming agents Emedastine No No sensory organs Emtricitabine No No anti-infective for systemic use Enfuvirtide Yes Yes anti-infective for systemic use Entacapone No No nervous system Entecavir No No anti-infective for systemic use Eplerenone No No cardiovascular system Epoprostenol Yes No blood and blood-forming agents Eprosartan No No cardiovascular system Eptifibatide No No blood and blood-forming agents Eribulin Yes No antineoplastic and immunomodulating agents Erlotinib No No antineoplastic and immunomodulating agents Ertapenem No No anti-infective for systemic use Etanercept No Yes antineoplastic and immunomodulating agents Ethinyl estradiol/etonogestrel No No genitourinary system and sex hormones Etravirine No No anti-infective for systemic use Everolimus No No antineoplastic and immunomodulating agents Exemestane No No antineoplastic and immunomodulating agents Exenatide Yes No alimentary tract and metabolism Ezetimibe Yes No cardiovascular system Febuxostat No No musculoskeletal system Fexofenadine No No respiratory system Fingolimod Yes No antineoplastic and immunomodulating agents Fluticasone No No respiratory system Fondaparinux Yes No blood and blood-forming agents Formoterol No No respiratory system Fosaprepitant No No alimentary tract and metabolism [4] HEALTHCARE POLICY Vol.12 No.2, 2016

How Safe and Are First-in-Class Drugs Approved by Health Canada: A Cohort Study Frovatriptan No No nervous system Fulvestrant Yes No antineoplastic and immunomodulating agents Gadobenate No No not listed Galantamine No No nervous system Ganirelix Yes No systemic hormonal preparations, excluding sex hormones and insulins Gatifloxacin No No anti-infective for systemic use Gefitinib Yes No antineoplastic and immunomodulating agents Gemifloxacin No No anti-infective for systemic use Glatiramer Yes No antineoplastic and immunomodulating agents Glimepiride No No alimentary tract and metabolism Golimumab No No antineoplastic and immunomodulating agents Grepafloxacin No No anti-infective for systemic use Histrelin No No antineoplastic and immunomodulating agents Ibandronate No No musculoskeletal system Ibritumomab Yes No various Icodextrin No No not listed Idursulfase Yes No alimentary tract and metabolism Imatinib Yes Yes antineoplastic and immunomodulating agents Imiglucerase No Yes alimentary tract and metabolism Indacaterol No No respiratory system Infliximab Yes Yes antineoplastic and immunomodulating agents Insulin detemir No No alimentary tract and metabolism Insulin glulisine No No alimentary tract and metabolism Interferon beta-1a No Yes antineoplastic and immunomodulating agents Ipilimumab Yes No antineoplastic and immunomodulating agents Irbesartan No No cardiovascular system Irinotecan No Yes antineoplastic and immunomodulating agents Lacosamide No No nervous system Lanreotide No Yes systemic hormonal preparations, excluding sex hormones and insulins Lanthanum No No various Lapatinib No No antineoplastic and immunomodulating agents Laronidase Yes Yes alimentary tract and metabolism [5] HEALTHCARE POLICY Vol.12 No.2, 2016

Joel Lexchin Latanoprost Yes No sensory organs Leflunomide Yes No antineoplastic and immunomodulating agents Lenalidomide No Yes antineoplastic and immunomodulating agents Letrozole No No antineoplastic and immunomodulating agents Levetiracetam No No nervous system Linagliptin No No alimentary tract and metabolism Linezolid Yes No anti-infective for systemic use Liraglutide No No alimentary tract and metabolism Lisdexamfetamine No No nervous system Lopinavir/ritonavir No No anti-infective for systemic use Loteprednol No No sensory organs Lurasidone No No nervous system Maraviroc Yes No anti-infective for systemic use Meloxicam No No musculoskeletal system Memantine Yes No nervous system Mequinol/tretinoin No No dermatologicals Methylnaltrexone Yes Yes alimentary tract and metabolism Micafungin No No anti-infective for systemic use Miglustat Yes No alimentary tract and metabolism Mirtazapine No No nervous system Modafinil Yes Yes nervous system Montelukast No No respiratory system Moxifloxacin No No anti-infective for systemic use Naratriptan No No nervous system Natalizumab Yes No antineoplastic and immunomodulating agents Nateglinide No No alimentary tract and metabolism Nebivolol No No cardiovascular system Nelfinavir No No anti-infective for systemic use Nepafenac No No sensory organs Nesiritide Yes No cardiovascular system Nevirapine Yes No anti-infective for systemic use Nilotinib No No antineoplastic and immunomodulating agents [6] HEALTHCARE POLICY Vol.12 No.2, 2016

How Safe and Are First-in-Class Drugs Approved by Health Canada: A Cohort Study Ofatumumab No No antineoplastic and immunomodulating agents Olmesartan No No cardiovascular system Omalizumab Yes No respiratory system Orlistat Yes No alimentary tract and metabolism Oseltamivir No No anti-infective for systemic use Oxaliplatin No No antineoplastic and immunomodulating agents Oxcarbazepine No No nervous system Palifermin Yes Yes various Paliperidone No No nervous system Palivizumab Yes No anti-infective for systemic use Palonosetron No No alimentary tract and metabolism Panitumumab No No antineoplastic and immunomodulating agents Pantoprazole No No alimentary tract and metabolism Paricalcitol No No systemic hormonal preparations, excluding sex hormones and insulins Pazopanib No No antineoplastic and immunomodulating agents Pegaptanib Yes Yes sensory organs Pegfilgrastim No No antineoplastic and immunomodulating agents Peginterferon alfa-2a No No antineoplastic and immunomodulating agents Peginterferon alfa-2b No No antineoplastic and immunomodulating agents Pegvisomant Yes No systemic hormonal preparations, excluding sex hormones and insulins Pemetrexed No Yes antineoplastic and immunomodulating agents Penciclovir No No anti-infective for systemic use Perindopril No No cardiovascular system Pimecrolimus No No dermatologicals Pioglitazone No No alimentary tract and metabolism Plerixafor Yes No antineoplastic and immunomodulating agents Posaconazole No Yes anti-infective for systemic use Pramipexole Yes No nervous system Prasugrel No No blood and blood-forming agents Pregabalin No No nervous system Quetiapine No No nervous system Rabeprazole No No alimentary tract and metabolism [7] HEALTHCARE POLICY Vol.12 No.2, 2016

Joel Lexchin Raloxifene Yes No genitourinary system and sex hormones Raltegravir Yes Yes anti-infective for systemic use Ranibizumab No Yes sensory organs Rasagiline No No nervous system Rasburicase Yes No various Recombinant-methionyl interferon consensus 1 No No antineoplastic and immunomodulating agents Repaglinide Yes No alimentary tract and metabolism Rilpivirine No No anti-infective for systemic use Riluzole Yes Yes nervous system Risedronate No No musculoskeletal system Rituximab Yes Yes antineoplastic and immunomodulating agents Rivaroxaban No No blood and blood-forming agents Rivastigmine No No nervous system Rizatriptan No No nervous system Rofecoxib No No musculoskeletal system Roflumilast Yes No respiratory system Romiplostim Yes No blood and blood-forming agents Ropinirole No No nervous system Rosiglitazone No No alimentary tract and metabolism Rosuvastatin No No cardiovascular system Rufinamide No No nervous system Sapropterin Yes Yes alimentary tract and metabolism Saxagliptin No No alimentary tract and metabolism Sevelamer No No various Sibutramine Yes No alimentary tract and metabolism Sildenafil Yes Yes genitourinary system and sex hormones Silodosin No No genitourinary system and sex hormones Sirolimus Yes No antineoplastic and immunomodulating agents Sitagliptin Yes No alimentary tract and metabolism Sodium oxybate No Yes nervous system Solifenacin No No genitourinary system and sex hormones Sorafenib Yes No antineoplastic and immunomodulating agents [8] HEALTHCARE POLICY Vol.12 No.2, 2016

How Safe and Are First-in-Class Drugs Approved by Health Canada: A Cohort Study Sunitinib No Yes antineoplastic and immunomodulating agents Tadalafil No No genitourinary system and sex hormones Tamsulosin No No genitourinary system and sex hormones Tapentadol No No nervous system Tegaserod Yes No alimentary tract and metabolism Telaprevir No Yes anti-infective for systemic use Telbivudine No No anti-infective for systemic use Telithromycin Yes No anti-infective for systemic use Telmisartan No No cardiovascular system Temozolomide No No antineoplastic and immunomodulating agents Temsirolimus Yes No antineoplastic and immunomodulating agents Tenecteplase No No blood and blood-forming agents Tenofovir No No anti-infective for systemic use Ticagrelor No No blood and blood-forming agents Tigecycline Yes No anti-infective for systemic use Tiotropium No No respiratory system Tipranavir No No anti-infective for systemic use Tirofiban No No blood and blood-forming agents Tizanidine Yes No musculoskeletal system Tocilizumab Yes No antineoplastic and immunomodulating agents Tolcapone Yes No nervous system Tolterodine No No genitourinary system and sex hormones Tolvaptan No No cardiovascular system Topiramate No No nervous system Topotecan Yes No antineoplastic and immunomodulating agents Tramadol No No nervous system Trastuzumab Yes No antineoplastic and immunomodulating agents Travoprost No No sensory organs Treprostinil No No blood and blood-forming agents Triptorelin No No antineoplastic and immunomodulating agents Trospium No No genitourinary system and sex hormones Trovafloxacin No No anti-infective for systemic use [9] HEALTHCARE POLICY Vol.12 No.2, 2016

Joel Lexchin Ustekinumab Yes No antineoplastic and immunomodulating agents Valdecoxib No No musculoskeletal system Valsartan No No cardiovascular system Vandetanib No No antineoplastic and immunomodulating agents Vardenafil No No genitourinary system and sex hormones Varenicline Yes No nervous system Vemurafenib Yes Yes antineoplastic and immunomodulating agents Verteporfin Yes Yes sensory organs Voriconazole No No anti-infective for systemic use Vorinostat Yes No antineoplastic and immunomodulating agents Zafirlukast Yes No respiratory system Zaleplon No No nervous system Zanamivir Yes No anti-infective for systemic use Zoledronic acid No No musculoskeletal system Zolmitriptan No No nervous system [10] HEALTHCARE POLICY Vol.12 No.2, 2016